Optinose

Major Drugs - Yardley, Pennsylvania, US

Optinose Employees
Mickey Malik

Director, Thought Leader Engagement

Contact Mickey Malik

Brian Lorenz

Director, Sales Operations

Contact Brian Lorenz

Susan Torchio

Director, Global Clinical Operations

Contact Susan Torchio

Brandy Young

Regional Business Director

Contact Brandy Young

Kelly Bisson

National Sales Director

Contact Kelly Bisson

Pamela Gray

Sr. Director, Quality

Contact Pamela Gray

View All Optinose Employees Contact All Optinose Employees
Optinose Senior Management
Keith Goldan

Chief Financial Officer

Contact Keith Goldan

Ramy Mahmoud

president and chief operating officer

Contact Ramy Mahmoud

Keith Goldan

Chief Financial Officer

Contact Keith Goldan

Michele Janis

Vice President of Finance & Chief Financial Officer

Contact Michele Janis

Joe Scodari

Chairman Of The Board

Contact Joe Scodari

View All Optinose Employees Contact All Optinose Employees
Optinose Details

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

Employees: 250 - 499
HQ: (267) 364-3500
Location: Yardley, Pennsylvania, US
Revenue: $77.5 million
Rhinosinusitis Drug Development Optinose Cfo Optinose Is There Hair Lining Your Throat Opti New Jersey
Optinose Technologies
Email Providers

Outlook

Load Balancers

Microsoft-IIS

Domain Name Services

CSC Corporate Domains

Other

Microsoft Office 365

Hosting

Rackspace

View All Technologies Used At Optinose

Contacting Optinose: Connect with Executives and Employees

Get in Touch with Optinose Executives and Employees

Connecting with Optinose's Executives and Workforce

Accessing Contact Information for Optinose Executives

Connecting with Optinose: Reach Out to Their Team

Discover How to Contact Optinose Executives and Staff

Looking to connect with Optinose executives or employees?

Seeking to Get in Touch with Optinose Executives or Staff?

Want to Reach Out to Optinose Executives or Team Members?

In Search of Contact Details for Optinose Professionals?

Connecting with Optinose: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z